Quality of Life Research

, Volume 21, Issue 6, pp 993–1003 | Cite as

The associations among coping, nadir CD4+ T-cell count, and non-HIV-related variables with health-related quality of life among an ambulatory HIV-positive patient population




We investigated HRQoL among HIV-positive outpatients from October, 2006-December, 2007, incorporating medical chart review, and a survey of coping styles.


Consented HIV-positive patients receiving medical care at University of Colorado Denver, with HAART as first antiretroviral regimen, completed the MOS-HIV and Brief COPE survey instruments. Linear regression identified a priori factors hypothesized to be associated with the MOS-HIV composite mental and physical health scores (MHS, PHS). Brief COPE survey maladaptive and adaptive coping components were added to the models and retained if significant.


Among the 157 patient cohort, parsimonious multivariable linear regression models (P < 0.05) indicated higher nadir CD4+ T-cell counts and adaptive coping were associated with a higher MHS; public/no insurance, mental illness, current number of non-HIV medications, and maladaptive coping were inversely associated with MHS. Nadir CD4+ T-cell count and efavirenz use were associated with a higher PHS; mental illness, current number of non-HIV mediations, and maladaptive coping were inversely associated with PHS.


Factors independently associated with lower MHS and lower PHS include lower nadir CD4+ T-cell counts, and use of maladaptive coping. Efforts to reduce use of maladaptive coping strategies and earlier identification and treatment of HIV may improve HRQoL in HIV-positive patients.


HIV Nadir CD4+ T-cell count Coping Quality of life 



Acquired immunodeficiency syndrome


Antiretroviral therapy




Highly active antiretroviral therapy


Human immunodeficiency virus


Health-related quality of life


Infectious disease group practice


Intravenous drug user


Inter-quartile range


Mental health score


Medical outcomes study


Men who have sex with men


Nucleoside analog reverse transcriptase inhibitor


Non-nucleoside analog reverse transcriptase inhibitor


Physical health score


Protease inhibitor


Standard deviation


University of Colorado Health Sciences Center



University of Colorado Health Sciences Center Adult General Clinical Research Center National Institutes of Health grant MO1 #RR00051 provided funding for patient participation honoraria.

Conflicts of interest

Dr. Armon has no conflicts of interest. Dr. Lichtenstein receives research support from Merck, Pfizer, and TaiMed. He serves on advisory boards for Abbott, Merck, Bristol-Myers Squibb, Gilead, and Tibotec.


  1. 1.
    National Institutes of Health. (1999). NIAID-Supported scientists discover origin of HIV-1. http://www3.niaid.nih.gov/news/newsreleases/1999/hivorigin.htm.
  2. 2.
    National Institutes of Health. (2004). How HIV causes AIDS. http://www.niaid.nih.gov/factsheets/howhiv.htm.
  3. 3.
    Palella, F. J., Jr., Delaney, K. M., Moorman, A. C., et al. (1998). Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators. New England Journal of Medicine, 338(13), 853–860.PubMedCrossRefGoogle Scholar
  4. 4.
    US Public Health Service. (2006). Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. www.aidsinfo.nih.gov/guidelines/default_db2.asp?id=50.
  5. 5.
    US Public Health Service. (2011). Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. www.aidsinfo.nih.gov.
  6. 6.
    Burgoyne, R. W., Rourke, S. B., Behrens, D. M., & Salit, I. E. (2004). Long-term quality-of-life outcomes among adults living with HIV in the HAART era: The interplay of changes in clinical factors and symptom profile. AIDS and Behavior, 8(2), 151–163.PubMedCrossRefGoogle Scholar
  7. 7.
    Vidrine, D. J., Amick, B. C., I. I. I., Gritz, E. R., & Arduino, R. C. (2003). Functional status and overall quality of life in a multiethnic HIV-positive population. AIDS Patient Care & STDs, 17(4), 187–197.CrossRefGoogle Scholar
  8. 8.
    Preau, M., Vincent, E., Spire, B., et al. (2005). Health-related quality of life and health locus of control beliefs among HIV-infected treated patients. Journal of Psychosomatic Research, 59, 407–413.PubMedCrossRefGoogle Scholar
  9. 9.
    Campsmith, M. L., Nakashima, A. K., & Davidson, A. J. (2003). Self-reported health-related quality of life in persons with HIV infection: results from a multi-site interview project. Health & Quality of Life Outcomes, 1, 12.CrossRefGoogle Scholar
  10. 10.
    Dougall, A. L., Smith, A. W., Somers, T. J., Posluszny, D. M., Rubinstein, W. S., & Baum, A. (2009). Coping with genetic testing for breast cancer susceptibility. Psychosomatic Medicine, 71(1), 98–105.PubMedCrossRefGoogle Scholar
  11. 11.
    Fogel, J. (2004). Internet breast health information use and coping among women with breast cancer. Cyberpsychology & Behavior, 7(1), 59–63.CrossRefGoogle Scholar
  12. 12.
    Olley, B. O., Seedat, S., & Stein, D. J. (2006). Persistence of psychiatric disorders in a cohort of HIV/AIDS patients in South Africa: A 6-month follow-up study. Journal of Psychosomatic Research, 61(4), 479–484.PubMedCrossRefGoogle Scholar
  13. 13.
  14. 14.
    Mauskopf, J., Kitahata, M., Kauf, T., Richter, A., & Tolson, J. (2005). HIV antiretroviral treatment: Early versus later. Journal of Acquired Immune Deficiency Syndromes: JAIDS, 39(5), 562–569.PubMedGoogle Scholar
  15. 15.
    Jia, H., Uphold, C. R., Wu, S., Chen, G. J., & Duncan, P. W. (2005). Predictors of changes in health-related quality of life among men with HIV infection in the HAART era. AIDS Patient Care & STDs, 19(6), 395–405.CrossRefGoogle Scholar
  16. 16.
    Carrieri, P., Spire, B., Duran, S., et al. (2003). Health-related quality of life after 1 year of highly active antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes: JAIDS, 32(1), 38–47.PubMedCrossRefGoogle Scholar
  17. 17.
    Preau, M., Leport, C., Salmon-Ceron, D., et al. (2004). Health-related quality of life and patient-provider relationships in HIV-infected patients during the first 3 years after starting PI-containing antiretroviral treatment. AIDS Care, 16(5), 649–661.PubMedCrossRefGoogle Scholar
  18. 18.
    Preau, M., Protopopescu, C., Spire, B., et al. (2007). Health related quality of life among both current and former injection drug users who are HIV-infected. Drug and Alcohol Dependence, 86(2–3), 175–182.PubMedCrossRefGoogle Scholar
  19. 19.
    Vosvick, M., Koopman, C., Gore-Felton, C., Thoresen, C., Krumboltz, J., & Spiegel, D. (2003). Relationship of functional quality of life to strategies for coping with the stress of living with HIV/AIDS. Psychosomatics, 44(1), 51–58.PubMedCrossRefGoogle Scholar
  20. 20.
    Jia, H., Uphold, C. R., Zheng, Y., et al. (2007). A further investigation of health-related quality of life over time among men with HIV infection in the HAART era. Quality of Life Research, 16, 961–968.PubMedCrossRefGoogle Scholar
  21. 21.
    Perez, J. E., Chartier, M., Koopman, C., Vosvick, M., Gore-Felton, C., & Spiegel, D. (2009). Spiritual striving, acceptance coping, and depressive symptoms among Adults living with HIV/AIDS. Journal of Health Psychology, 14(1), 88–97.PubMedCrossRefGoogle Scholar
  22. 22.
    Maggiolo, F. (2009). Efavirenz: A decade of clinical experience in the treatment of HIV. Journal of Antimicrobial Chemotherapy, 64(5), 910–928.PubMedCrossRefGoogle Scholar
  23. 23.
    Tozzi, V., Balestra, P., Galgani, S., et al. (2003). Neurocognitive performance and quality of life in patients with HIV infection. AIDS Research and Human Retroviruses, 19(8), 643–652.PubMedCrossRefGoogle Scholar
  24. 24.
    Robertson, K. R., Smurzynski, M., Parsons, T. D., et al. (2007). The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS, 21(14), 1915–1921.PubMedCrossRefGoogle Scholar
  25. 25.
    Lichtenstein, K. A., Armon, C., Buchacz, K., et al. (2008). Initiation of antiretroviral therapy at CD4 cell counts >/=350 cells/mm3 does not increase incidence or risk of peripheral neuropathy, anemia, or renal insufficiency. Journal of Acquired Immune Deficiency Syndromes: JAIDS, 47(1), 27–35.PubMedCrossRefGoogle Scholar
  26. 26.
    D:A:D Study Group. (2008). Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: A multi-cohort collaboration. Lancet, April, 1417–1426.Google Scholar
  27. 27.
    Lichtenstein, K. A., Armon, C., Buchacz, K., et al. (2010). Low CD4+ T cell count is a risk factor for cardiovascular disease events in the HIV outpatient study. Clinical Infectious Diseases, 51(4), 435–447.CrossRefGoogle Scholar
  28. 28.
    American Association of Diabetes Educators. (2009). Self-care behaviors. http://www.diabeteseducator.org/ProfessionalResources/AADE7/.
  29. 29.
    Centers for Disease Control and Prevention. (2009). Compendium of Evidence-Based HIV Prevention Interventions. http://www.cdc.gov/hiv/topics/research/prs/evidence-based-interventions.htm.
  30. 30.
    Centers for Disease Control and Prevention. (2009). Healthy living project. http://www.cdc.gov/hiv/topics/research/prs/resources/factsheets/healthy-living.htm.

Copyright information

© Springer Science+Business Media B.V. 2011

Authors and Affiliations

  1. 1.Children’s Hospital ColoradoAuroraUSA
  2. 2.National Jewish HealthDenverUSA

Personalised recommendations